Martin Feuchtenberger1,2, Lisa Kraus3, Axel Nigg4, Hendrik Schulze-Koops5, Arne Schäfer6,7. 1. Fachbereich Rheumatologie, MED|BAYERN OST Medizinische Versorgungszentren Altötting Burghausen, Rheumatologie Krankenhausstraße 1, 84489, Burghausen, Germany. m.feuchtenberger@innklinikum.de. 2. Medizinische Klinik und Poliklinik II, Klinikum der Universität Würzburg, Würzburg, Germany. m.feuchtenberger@innklinikum.de. 3. Medizinische Klinik III, Klinikum der Universität Augsburg, Augsburg, Germany. 4. Fachbereich Rheumatologie, MED|BAYERN OST Medizinische Versorgungszentren Altötting Burghausen, Rheumatologie Krankenhausstraße 1, 84489, Burghausen, Germany. 5. Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany. 6. Medizinische Klinik und Poliklinik II, Klinikum der Universität Würzburg, Würzburg, Germany. 7. Diabetes Zentrum Mergentheim, Bad Mergentheim, Germany.
Abstract
OBJECTIVES: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis on long-term methotrexate treatment. To assess the risk of liver fibrosis in patients with rheumatoid arthritis treated with methotrexate, non-invasive, ultrasound-based elastography [acoustic radiation force impulse (ARFI) imaging] was applied. METHODS: In total, 119 patients were assessed using acoustic radiation force impulse (ARFI) imaging between July 2018 and April 2019. In a cross-sectional, single-centre study design, ARFI scores were compared between patient subgroups with (n = 65) and without (n = 54) methotrexate exposure. The main outcome variable was the mean fibrosis score as measured by the ARFI method. The mean shear wave velocity was calculated from 10 valid ARFI measurements for each patient. Inferential statistical analyses (between group) were performed using ANOVA for independent samples in the case of continuous outcome variables. RESULTS: Sixty-five patients with and fifty-four patients without MTX exposure were assessed using the ARFI elastography method. Participating patients on MTX medication (1.113 m/s) showed ARFI scores that were comparable to those of participants without MTX exposure (1.062 m/s); P = 0.228. The mean cumulative dose in the group of MTX-exposed patients was 3602 mg. CONCLUSION: The mean value of the repeated determination of liver density using ARFI imaging did not differ significantly between the MTX-exposed and MTX-naive patients with RA. No increased rate of liver fibrosis was found among RA patients treated with MTX.
OBJECTIVES: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis on long-term methotrexate treatment. To assess the risk of liver fibrosis in patients with rheumatoid arthritis treated with methotrexate, non-invasive, ultrasound-based elastography [acoustic radiation force impulse (ARFI) imaging] was applied. METHODS: In total, 119 patients were assessed using acoustic radiation force impulse (ARFI) imaging between July 2018 and April 2019. In a cross-sectional, single-centre study design, ARFI scores were compared between patient subgroups with (n = 65) and without (n = 54) methotrexate exposure. The main outcome variable was the mean fibrosis score as measured by the ARFI method. The mean shear wave velocity was calculated from 10 valid ARFI measurements for each patient. Inferential statistical analyses (between group) were performed using ANOVA for independent samples in the case of continuous outcome variables. RESULTS: Sixty-five patients with and fifty-four patients without MTX exposure were assessed using the ARFI elastography method. Participating patients on MTX medication (1.113 m/s) showed ARFI scores that were comparable to those of participants without MTX exposure (1.062 m/s); P = 0.228. The mean cumulative dose in the group of MTX-exposed patients was 3602 mg. CONCLUSION: The mean value of the repeated determination of liver density using ARFI imaging did not differ significantly between the MTX-exposed and MTX-naive patients with RA. No increased rate of liver fibrosis was found among RApatients treated with MTX.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Bernard Combe; Robert Landewe; Claire I Daien; Charlotte Hua; Daniel Aletaha; Jose María Álvaro-Gracia; Margôt Bakkers; Nina Brodin; Gerd R Burmester; Catalin Codreanu; Richard Conway; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Joao Fonseca; Karim Raza; Lucía Silva-Fernández; Josef S Smolen; Diana Skingle; Zoltan Szekanecz; Tore K Kvien; Annette van der Helm-van Mil; Ronald van Vollenhoven Journal: Ann Rheum Dis Date: 2016-12-15 Impact factor: 19.103
Authors: M Friedrich-Rust; J Nierhoff; M Lupsor; I Sporea; C Fierbinteanu-Braticevici; D Strobel; H Takahashi; M Yoneda; T Suda; S Zeuzem; E Herrmann Journal: J Viral Hepat Date: 2011-10-30 Impact factor: 3.728
Authors: J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103
Authors: Josef S Smolen; Daniel Aletaha; Anne Barton; Gerd R Burmester; Paul Emery; Gary S Firestein; Arthur Kavanaugh; Iain B McInnes; Daniel H Solomon; Vibeke Strand; Kazuhiko Yamamoto Journal: Nat Rev Dis Primers Date: 2018-02-08 Impact factor: 52.329
Authors: C Fiehn; J Holle; C Iking-Konert; J Leipe; C Weseloh; M Frerix; R Alten; F Behrens; C Baerwald; J Braun; H Burkhardt; G Burmester; J Detert; M Gaubitz; A Gause; E Gromnica-Ihle; H Kellner; A Krause; J Kuipers; H-M Lorenz; U Müller-Ladner; M Nothacker; H Nüsslein; A Rubbert-Roth; M Schneider; H Schulze-Koops; S Seitz; H Sitter; C Specker; H-P Tony; S Wassenberg; J Wollenhaupt; K Krüger Journal: Z Rheumatol Date: 2018-08 Impact factor: 1.372